Guo-Nan Zhang
Overview
Explore the profile of Guo-Nan Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Yuan Z, Zhang G, Li Q, Cui M, Cheng W, et al.
Oncologist
. 2024 Nov;
30(1).
PMID: 39494888
Background: This study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) for patients with partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer. Methods: Patients with partially platinum-sensitive,...
2.
Chen F, Zhang G, Lei W, Zhou S, Zhang Y, Liu L, et al.
Gynecol Oncol
. 2023 Sep;
178:8-13.
PMID: 37734188
Background: We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN,...
3.
Wang D, Shi X, Zhang C, Zhang J, Liu H, Huang J, et al.
Gynecol Oncol
. 2023 Jan;
170:25-31.
PMID: 36608384
Objective: To assess the actual clinical application of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance therapy in Chinese patients with recurrent ovarian cancer, and to explore prognostic factors associated with...
4.
Li X, Cheng X, Zhang G, Wang X, Huang J
J Ovarian Res
. 2022 Aug;
15(1):96.
PMID: 35971131
Pegylated liposomal doxorubicin (PLD) is a nano-doxorubicin anticancer agent. It was used as early as 2014 to treat ovarian and breast cancer, multiple myeloma and Kaposi's sarcoma. The 2018 National...
5.
Li X, Zhu Y, Zhang G, Huang J, Pei L
J Ovarian Res
. 2021 Mar;
14(1):42.
PMID: 33750444
Background: Previous meta-analysis studies suggested that pegylated liposomal doxorubicin (PLD) may improve the survival rate of patients with recurrent ovarian cancer. The aim of the present meta-analysis, then, was to...
6.
Zhu Y, Leng X, Zhang G, Huang Z, Qiu L, Huang W
Cancer Med
. 2020 Sep;
9(21):7943-7953.
PMID: 32869506
Background: To evaluate the performance of transvaginal sonoelastography (TVSE) for differential diagnosis between malignant and benign cervical lesions using a meta-analysis. Methods: An independent literature search was conducted on the...
7.
Zhu Y, Zhang G, Shi Y, Cui L, Leng X, Huang J
Ann Transl Med
. 2019 Jun;
7(9):203.
PMID: 31205921
Perineural invasion (PNI) in early-stage cervical cancer, is associated with multiple high-risk factors and represents a poor outcome in the patients. For nerve-sparing radical hysterectomy (NSRH) to become a standard...
8.
Zhu Y, Zhang G, Zhang R, Shi Y, Wang D, He R
Medicine (Baltimore)
. 2017 Sep;
96(38):e7731.
PMID: 28930821
Rationale: Epithelioid trophoblastic tumor (ETT) is a distinctive but rare gestational trophoblastic neoplasia (GTN) composed of chorionic-type intermediate trophoblast cells. Approximately 50% ETT arose from the uterine cervix or lower...
9.
Liu H, Zhu Y, Zhang G, Wang C, Li C, Shi Y
Sci Rep
. 2016 Aug;
6:31229.
PMID: 27503773
Uterine sarcoma, a rare solid tumor in uterus, is difficult to identify in the early stage from some benign uterine tumors, such as uterine fibroids. Hence, uterine sarcoma may be...
10.
Zhu Y, Wang C, Zhang G, Shi Y, Xu S, Jia S, et al.
World J Surg Oncol
. 2016 Jan;
14(1):17.
PMID: 26791568
Background: The present of malignant transformation in struma ovarii is exceedingly rare. Malignant struma ovarii is usually asymptomatic and infrequently diagnosed preoperatively. Because of its rarity, there is no consensus...